1	didanosine	tenofovir disoproxil fumarate	3	3	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].	3364	
5	alprazolam	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.	596	679314
5	alprazolam	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.	596	114289
5	alprazolam	terfenadine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.	596	42330
5	alprazolam	venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.	596	39786
5	caffeine	venlafaxine	51	51	true	negative	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.	1886	39786
5	cimetidine	cimetidine	3	3	true	positive	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.	2541	2541
5	desipramine	metoprolol	35	36	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol.	3247	6918
5	diazepam	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.	3322	679314
5	diazepam	alprazolam	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.	3322	596
5	diazepam	diazepam	54	54	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).	3322	3322
5	diazepam	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.	3322	114289
5	diazepam	monoamine oxidase inhibitors	54	55	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  7.9 Monoamine Oxidase Inhibitors    See Contraindications (4) and Warnings and Precautions (5.2).	3322	
5	diazepam	risperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.	3322	35636
5	diazepam	terfenadine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.	3322	42330
5	diazepam	venlafaxine	54	54	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).	3322	39786
5	haloperidol	haloperidol	11	11	true	positive	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.	5093	5093
5	imipramine	desipramine	34	35	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.	5691	3247
5	imipramine	imipramine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.	5691	5691
5	imipramine	metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol.	5691	6918
5	imipramine	venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.	5691	39786
5	indinavir	indinavir	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.	114289	114289
5	indinavir	venlafaxine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.	114289	39786
5	ketoconazole	ketoconazole	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.	6135	6135
5	o-desmethylvenlafaxine	desipramine	37	35	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol.  Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.		3247
5	o-desmethylvenlafaxine	ketoconazole	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.		6135
5	o-desmethylvenlafaxine	metoprolol	37	38	true	negative	Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.  Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.		6918
5	o-desmethylvenlafaxine	venlafaxine 50 mg	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.		39786
5	risperidone	9-hydroxyrisperidone	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.	35636	679314
5	risperidone	alprazolam	44	46	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.	35636	596
5	risperidone	risperidone	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.	35636	35636
5	risperidone	venlafaxine	43	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.	35636	39786
5	terfenadine	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.	42330	679314
5	terfenadine	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.	42330	114289
5	terfenadine	risperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.	42330	35636
5	venlafaxine	9-hydroxyrisperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.	39786	679314
5	venlafaxine	desipramine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.	39786	3247
5	venlafaxine	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.	39786	114289
5	venlafaxine	metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol.	39786	6918
5	venlafaxine	monoamine oxidase inhibitors	54	55	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).  7.9 Monoamine Oxidase Inhibitors    See Contraindications (4) and Warnings and Precautions (5.2).	39786	
5	venlafaxine	risperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.	39786	35636
5	venlafaxine	terfenadine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.	39786	42330
5	venlafaxine	venlafaxine 75 mg	31	33	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.  The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h).	39786	39786
5	venlafaxine 50 mg	ketoconazole	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.	39786	6135
5	venlafaxine hydrochloride	9-hydroxyrisperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.	39786	679314
5	venlafaxine hydrochloride	metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].	39786	6918
5	venlafaxine hydrochloride	risperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.	39786	35636
7	9-hydroxyrisperidone	clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.	679314	2626
7	9-hydroxyrisperidone	levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.	679314	6375
7	amitriptyline	9-hydroxyrisperidone	4	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.	704	679314
7	amitriptyline	levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.	704	6375
7	amitriptyline	ranitidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.	704	9143
7	carbamazepine	carbamazepine	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.	2002	2002
7	carbamazepine	erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.	2002	4053
7	cimetidine	9-hydroxyrisperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.	2541	679314
7	cimetidine	amitriptyline	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.	2541	704
7	cimetidine	cimetidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.	2541	2541
7	cimetidine	levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.	2541	6375
7	cimetidine	risperidone	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.	2541	35636
7	clozapine	9-hydroxyrisperidone	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.	2626	679314
7	clozapine	cimetidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.	2626	2541
7	clozapine	valproate	7	9	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).	2626	40254
7	digoxin	digoxin	11	11	true	negative	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.	3407	3407
7	digoxin	valproate	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.	3407	40254
7	fluoxetine	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.	4493	679314
7	fluoxetine	fluoxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.	4493	4493
7	fluoxetine	risperidone	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.	4493	35636
7	levodopa	9-hydroxyrisperidone	3	4	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.	6375	679314
7	levodopa	cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.	6375	2541
7	paroxetine	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.	32937	679314
7	paroxetine	fluoxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.	32937	4493
7	paroxetine	paroxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.	32937	32937
7	ranitidine	9-hydroxyrisperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.	9143	679314
7	ranitidine	cimetidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.	9143	2541
7	ranitidine	clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.	9143	2626
7	ranitidine	levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.	9143	6375
7	ranitidine	ranitidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.	9143	9143
7	risperidone	cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.	35636	2541
7	risperidone	clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.	35636	2626
7	risperidone	digoxin	9	11	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.	35636	3407
7	risperidone	fluoxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.	35636	4493
7	risperidone	paroxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.	35636	32937
7	risperidone	ranitidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.	35636	9143
7	valproate	9-hydroxyrisperidone	10	12	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].	40254	679314
7	valproate	clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).	40254	2626
7	valproate	digoxin	9	11	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.	40254	3407
7	valproate	risperidone	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).	40254	35636
7	valproate	valproate	9	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).	40254	40254
9	alosetron	diltiazem	42	44	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex® (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.	85248	3443
9	amitriptyline	thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	704	10502
9	amitriptyline	triptans	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.	704	
9	aspirin	fluvoxamine	54	55	true	positive	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.	1191	42355
9	atenolol	atenolol 100 mg	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.	1202	1202
9	atenolol	fluvoxamine maleate 100 mg	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.	1202	42355
9	benzodiazepines	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.		
9	benzodiazepines	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.		8183
9	benzodiazepines	theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.		10438
9	carbamazepine	carbamazepine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.	2002	2002
9	carbamazepine	clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).	2002	2626
9	carbamazepine	ethanol	21	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.	2002	448
9	clomipramine	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	2597	704
9	clomipramine	thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	2597	10502
9	clomipramine	triptans	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.	2597	
9	diazepam	fluvoxamine	16	17	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.	3322	42355
9	diazepam	lorazepam	16	17	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.	3322	6470
9	digoxin	digoxin	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.	3407	3407
9	digoxin	fluvoxamine	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.	3407	42355
9	digoxin	fluvoxamine maleate 100 mg	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.	3407	42355
9	digoxin	mexiletine	43	45	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).	3407	6926
9	digoxin	tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex® (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.	3407	10898
9	diltiazem	alosetron	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex® (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.	3443	85248
9	diltiazem	digoxin	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.	3443	3407
9	diltiazem	diltiazem	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.	3443	3443
9	diltiazem	fluvoxamine maleate 100 mg	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.	3443	42355
9	fluvoxamine	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	42355	704
9	fluvoxamine	atenolol	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.	42355	1202
9	fluvoxamine	atenolol 100 mg	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.	42355	1202
9	fluvoxamine	benzodiazepines	10	11	true	positive	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	42355	
9	fluvoxamine	carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.	42355	2002
9	fluvoxamine	clomipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	42355	2597
9	fluvoxamine	clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).	42355	2626
9	fluvoxamine	digoxin	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.	42355	3407
9	fluvoxamine	diltiazem	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.	42355	3443
9	fluvoxamine	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.	42355	448
9	fluvoxamine	fluvoxamine maleate 100 mg	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.	42355	42355
9	fluvoxamine	imipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	42355	5691
9	fluvoxamine	lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.	42355	6470
9	fluvoxamine	metoprolol	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.	42355	6918
9	fluvoxamine	phenytoin	10	11	true	positive	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	42355	8183
9	fluvoxamine	triptans	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.	42355	
9	fluvoxamine maleate	alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.	42355	596
9	fluvoxamine maleate	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	42355	704
9	fluvoxamine maleate	atenolol	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.	42355	1202
9	fluvoxamine maleate	atenolol 100 mg	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.	42355	1202
9	fluvoxamine maleate	benzodiazepines	12	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).	42355	
9	fluvoxamine maleate	carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.	42355	2002
9	fluvoxamine maleate	clomipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	42355	2597
9	fluvoxamine maleate	clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).	42355	2626
9	fluvoxamine maleate	diazepam	17	16	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.	42355	3322
9	fluvoxamine maleate	digoxin	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.	42355	3407
9	fluvoxamine maleate	diltiazem	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.	42355	3443
9	fluvoxamine maleate	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.	42355	448
9	fluvoxamine maleate	fluvoxamine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	42355	42355
9	fluvoxamine maleate	fluvoxamine maleate 100 mg	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.	42355	42355
9	fluvoxamine maleate	imipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	42355	5691
9	fluvoxamine maleate	ketoconazole	12	10	true	positive	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).	42355	6135
9	fluvoxamine maleate	lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.	42355	6470
9	fluvoxamine maleate	methadone	24	25	true	positive	Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  Methadone: See WARNINGS AND PRECAUTIONS (5.8).	42355	6813
9	fluvoxamine maleate	metoprolol	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.	42355	6918
9	fluvoxamine maleate	mexiletine	43	45	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).	42355	6926
9	fluvoxamine maleate	omeprazole	12	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).	42355	7646
9	fluvoxamine maleate	phenytoin	12	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).	42355	8183
9	fluvoxamine maleate	propranolol	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.	42355	8787
9	fluvoxamine maleate	theophylline	12	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).	42355	10438
9	fluvoxamine maleate	thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	42355	10502
9	fluvoxamine maleate	tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	42355	57258
9	fluvoxamine maleate	triptans	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.	42355	
9	fluvoxamine maleate	tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex® (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.	42355	10898
9	fluvoxamine maleate	warfarin	12	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).	42355	11289
9	fluvoxamine maleate 100 mg	atenolol 100 mg	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.	42355	1202
9	imipramine	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	5691	704
9	imipramine	clomipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	5691	2597
9	imipramine	thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	5691	10502
9	imipramine	triptans	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.	5691	
9	lorazepam	alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.	6470	596
9	lorazepam	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.	6470	448
9	lorazepam	lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.	6470	6470
9	lotronex	diltiazem	42	44	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex® (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.	85248	3443
9	mexiletine	digoxin	45	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).	6926	3407
9	mexiletine	fluvoxamine	45	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).	6926	42355
9	mexiletine	fluvoxamine maleate 100 mg	45	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).	6926	42355
9	omeprazole	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	7646	
9	phenytoin	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	8183	
9	phenytoin	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	8183	7646
9	phenytoin	theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	8183	10438
9	pimozide	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	8331	
9	pimozide	fluvoxamine	11	10	true	positive	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	8331	42355
9	pimozide	fluvoxamine maleate	11	12	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).	8331	42355
9	pimozide	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	8331	7646
9	pimozide	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	8331	8183
9	pimozide	warfarin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	8331	11289
9	propranolol	diltiazem	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.	8787	3443
9	propranolol	mexiletine	46	45	true	positive	Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.	8787	6926
9	sumatriptan	sumatriptan	38	38	true	negative	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.	37418	37418
9	theophylline	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	10438	
9	theophylline	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	10438	8183
9	theophylline	pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	10438	8331
9	tizanidine	amitriptyline	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	57258	704
9	tizanidine	clomipramine	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	57258	2597
9	tizanidine	fluvoxamine	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	57258	42355
9	tizanidine	imipramine	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.	57258	5691
9	tryptophan	fluvoxamine maleate 100 mg	41	43	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex® (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.	10898	42355
9	warfarin	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	11289	
9	warfarin	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	11289	8183
9	warfarin	pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.	11289	8331
11	sertraline	cimetidine	1	1	true	positive	In a study assessing disposition of sertraline (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline mean AUC (50%), C max (24%) and half-life (26%) compared to the placebo group.	36437	2541
12	sertraline	desmethyldiazepam	1	2	true	positive	In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p < 0.03).  There was a 23% increase in T max for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p < 0.03).	36437	3155
12	sertraline	diazepam	1	1	true	positive	In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p < 0.03).	36437	3322
14	sertraline	pimozide	1	1	true	positive	In a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) co-adminis-tration to steady state was associated with a mean increase in pimozide AUC and C max of about 40%, but was not associated with any changes in EKG.	36437	8331
15	phenytoin	sertraline	1	1	true	negative	Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism.	8183	36437
15	phenytoin	sertraline 200 mg	1	1	true	negative	Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism.	8183	36437
16	sertraline 200 mg	carbamazepine	4	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).	36437	2002
16	sertraline 200 mg	cisapride	4	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).	36437	35255
16	terfenadine	sertraline 200 mg	2	4	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).	42330	36437
17	sertraline	sertraline	1	1	true	positive	In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose.	36437	36437
17	tolbutamide	sertraline	1	1	true	positive	In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose.	10635	36437
18	sertraline	atenolol	1	1	true	negative	Sertraline (100 mg) when administered to 10 healthy male subjects had no effect on the beta-adrenergic blocking ability of atenolol.	36437	1202
19	sertraline	digoxin	1	1	true	negative	In a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance.	36437	3407
22	ethinyl estradiol	fluconazole 50 mg	2	1	true	negative	Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women.  There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.	4124	4450
22	fluconazole	ethinyl estradiol	1	2	true	negative	Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women.  There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.	4450	4124
22	fluconazole	fluconazole 50 mg	1	1	true	positive	Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women.	4450	4450
22	fluconazole	levonorgestrel	1	2	true	negative	Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women.  There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.	4450	6373
22	levonorgestrel	ethinyl estradiol	2	2	true	negative	There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.	6373	4124
22	levonorgestrel	fluconazole 50 mg	2	1	true	negative	Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women.  There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.	6373	4450
23	cimetidine	cimetidine 600 mg	2	4	true	negative	After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax.  There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%).  However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.	2541	2541
23	cimetidine	fluconazole	1	1	true	negative	Fluconazole 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers.	2541	4450
23	cimetidine	fluconazole 100 mg	1	1	true	negative	Fluconazole 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers.	2541	4450
23	cimetidine 400 mg	cimetidine	1	1	true	negative	Fluconazole 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers.	2541	2541
23	cimetidine 400 mg	fluconazole	1	1	true	negative	Fluconazole 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers.	2541	4450
23	cimetidine 400 mg	fluconazole 100 mg	1	1	true	negative	Fluconazole 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers.	2541	4450
23	fluconazole	cimetidine 600 mg	2	4	true	negative	After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax.  There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%).  However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.	4450	2541
23	fluconazole 200 mg	cimetidine	4	2	true	negative	After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax.  There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%).  However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.	4450	2541
23	fluconazole 200 mg	cimetidine 600 mg	4	4	true	negative	However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.	4450	2541
23	fluconazole 200 mg	fluconazole	4	2	true	negative	After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax.  There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%).  However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.	4450	4450
24	fluconazole	fluconazole	1	1	true	positive	Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole.	4450	4450
24	rifampin	fluconazole	1	1	true	positive	Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole.	9384	4450
25	fluconazole 200 mg	fluconazole	1	1	true	positive	Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers.	4450	4450
25	phenytoin	fluconazole	1	1	true	positive	Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers.	8183	4450
25	phenytoin	fluconazole 200 mg	1	1	true	positive	Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers.	8183	4450
25	phenytoin	phenytoin	1	1	true	positive	Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers.	8183	8183
26	cyclosporine	cyclosporine	1	1	true	positive	Cyclosporine AUC and Cmax were determined before and after the administration of fluconazole 200 mg daily for 14 days in eight renal transplant patients who had been on cyclosporine therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks.	3008	3008
26	cyclosporine	fluconazole	1	1	true	negative	Cyclosporine AUC and Cmax were determined before and after the administration of fluconazole 200 mg daily for 14 days in eight renal transplant patients who had been on cyclosporine therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks.	3008	4450
26	fluconazole 200 mg	cyclosporine	1	1	true	negative	Cyclosporine AUC and Cmax were determined before and after the administration of fluconazole 200 mg daily for 14 days in eight renal transplant patients who had been on cyclosporine therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks.	4450	3008
28	fluconazole 200 mg	aminophylline	1	1	true	negative	The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers.	4450	689
28	fluconazole 200 mg	theophylline	1	1	true	negative	The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers.	4450	10438
28	theophylline	aminophylline	1	1	true	negative	The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers.	10438	689
29	fluconazole	tolbutamide	1	1	true	positive	In 13 normal male volunteers, there was significant increase in tolbutamide (500 mg single dose) AUC and Cmax following the administration of fluconazole.	4450	10635
29	tolbutamide	tolbutamide	1	1	true	positive	In 13 normal male volunteers, there was significant increase in tolbutamide (500 mg single dose) AUC and Cmax following the administration of fluconazole.	10635	10635
30	glipizide	fluconazole	1	1	true	positive	The AUC and Cmax of glipizide (2.5 mg single dose) were significantly increased following the administration of fluconazole in 13 normal male volunteers.	4821	4450
31	fluconazole	glyburide	1	1	true	positive	The AUC and Cmax of glyburide (5 mg single dose) were significantly increased following the administration of fluconazole in 20 normal male volunteers.	4450	4815
32	a 7	midazolam	3	1	true	negative	The effect of fluconazole on the pharmacokinetics and pharmacodynamics of midazolam was examined in a randomized, cross-over study in 12 volunteers.  In the study, subjects ingested placebo or 400 mg fluconazole on Day 1 followed by 200 mg daily from Day 2 to Day 6.  In addition, a 7.5 mg dose of midazolam was orally ingested on the first day, 0.05 mg/kg was administered intravenously on the fourth day, and 7.5 mg orally on the sixth day.		6960
32	midazolam	fluconazole	1	1	true	negative	The effect of fluconazole on the pharmacokinetics and pharmacodynamics of midazolam was examined in a randomized, cross-over study in 12 volunteers.	6960	4450
33	fluconazole	azithromycin	1	1	true	negative	An open-label, randomized, three-way crossover study in 18 healthy subjects assessed the effect of a single 800 mg oral dose of fluconazole on the pharmacokinetics of a single 1200 mg oral dose of azithromycin as well as the effects of azithromycin on the pharmacokinetics of fluconazole.	4450	18631
35	nitrofurantoin	magnesium trisilicate	1	1	true	positive	Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.	7454	29170
36	nitrofurantoin	probenecid	1	1	true	positive	Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.	7454	8698
36	sulfinpyrazone	nitrofurantoin	1	1	true	positive	Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.	10205	7454
42	azathioprine	basis	1	2	true	positive	In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 to 600 mg of allopurinol sodium for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.  Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects (see PRECAUTIONS- Drug Interactions).	1256	10795
42	mercaptopurine	azathioprine	1	1	true	positive	In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 to 600 mg of allopurinol sodium for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.	103	1256
42	mercaptopurine	basis	1	2	true	positive	In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 to 600 mg of allopurinol sodium for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.  Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects (see PRECAUTIONS- Drug Interactions).	103	10795
45	paroxetine	phenobarbital	2	1	true	positive	Phenobarbital induces many cytochrome P450 (oxidative) enzymes.  When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone.	32937	8134
46	paroxetine	phenytoin	1	1	true	positive	When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone.	32937	8183
46	paroxetine hydrochloride	phenytoin	4	2	true	positive	In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed.  No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).	32937	8183
47	9-hydroxyrisperidone	desipramine	6	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.	679314	3247
47	9-hydroxyrisperidone	paroxetine 20 mg	6	6	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.	679314	32937
47	9-hydroxyrisperidone	risperidone	6	5	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.	679314	35636
47	atomoxetine	paroxetine 20 mg	7	6	true	positive	In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.	38400	32937
47	desipramine	paroxetine 20 mg	4	6	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.	3247	32937
47	paroxetine	9-hydroxyrisperidone	4	6	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.	32937	679314
47	paroxetine	atomoxetine	5	7	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.	32937	38400
47	paroxetine	desipramine	2	4	true	positive	Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme.  In most patients (>90%), this CYP2D6 isozyme is saturated early during paroxetine dosing.  In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.	32937	3247
47	paroxetine	paroxetine 20 mg	4	6	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.	32937	32937
47	paroxetine	risperidone	3	5	true	positive	In most patients (>90%), this CYP2D6 isozyme is saturated early during paroxetine dosing.  In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.	32937	35636
47	risperidone	desipramine	5	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.	35636	3247
47	risperidone	paroxetine 20 mg	5	6	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.	35636	32937
48	paroxetine	terfenadine	1	1	true	negative	An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for  CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics.	32937	42330
49	lithium carbonate	paroxetine	1	1	true	positive	A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate.	42351	32937
49	lithium carbonate	paroxetine hydrochloride	1	1	true	positive	A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate.	42351	32937
49	paroxetine	paroxetine hydrochloride	1	1	true	positive	A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate.	32937	32937
51	paroxetine	fosamprenavir	1	1	true	positive	Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine.	32937	358262
51	paroxetine	ritonavir	1	1	true	positive	Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine.	32937	85762
51	ritonavir	fosamprenavir	1	1	true	positive	Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine.	85762	358262
53	quinidine	ketoconazole	1	1	true	positive	Perhaps because of competition for the P450 3A4metabolic pathway, quinidine levels rise when ketoconazole is coadministered.	9068	6135
54	diltiazem	diltiazem	1	1	true	positive	Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem.	3443	3443
54	diltiazem	quinidine	1	1	true	positive	Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem.	3443	9068
55	magnesium stearate	quinidine	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.	1368706	9068
55	magnesium stearate	quinidine sulfate	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.	1368706	9068
55	quinidine	hypromellose	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.	9068	27334
55	quinidine	polydextrose	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.	9068	1363053
55	quinidine	polyethylene glycol	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.	9068	8516
55	quinidine	povidone	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.	9068	8610
55	quinidine	triacetin	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.	9068	10756
55	quinidine sulfate	hypromellose	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.	9068	27334
55	quinidine sulfate	polydextrose	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.	9068	1363053
55	quinidine sulfate	polyethylene glycol	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.	9068	8516
55	quinidine sulfate	povidone	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.	9068	8610
55	quinidine sulfate	quinidine	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.	9068	9068
55	quinidine sulfate	quinidine sulfate	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.	9068	9068
55	triacetin	quinidine sulfate	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.	10756	9068
56	phenytoin	zonisamide	1	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.	8183	39998
56	zonisamide	carbamazepine	1	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.	39998	2002
56	zonisamide	valproate	1	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.	39998	40254
57	zonisamide	cimetidine	1	1	true	negative	Zonisamide single dose pharmacokinetic parameters were not affected by cimetidine (300 mg four times a day for 12 days).	39998	2541
58	zonisamide	zonisamide	1	1	true	positive	Zonisamide has been administered to 1,598 individuals during all clinical trials, only some of which were placebo-controlled.	39998	39998
59	carbamazepine	nefazodone	1	1	true	positive	Coadministration of carbamazepine with nefazodone results in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect.	2002	31565
61	phenothiazines	cimetidine	1	2	true	positive	Certain drugs, particularly the psychostimulants and the phenothiazines, increase plasma levels of concomitantly administered tricyclic antidepressants through competition for the same metabolic enzyme systems.  Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma concentrations of the tricyclic antidepressants.		2541
63	atenolol	nisoldipine	7	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.	1202	7435
63	cimetidine 400 mg	nisoldipine	1	1	true	positive	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.	2541	7435
63	nisoldipine	nisoldipine	1	1	true	positive	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.	7435	7435
63	phenytoin	atenolol	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.	8183	1202
63	phenytoin	nisoldipine	5	4	true	positive	CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.	8183	7435
63	phenytoin	propranolol	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.	8183	8787
63	propranolol	nisoldipine	7	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.	8787	7435
63	quinidine	nisoldipine	10	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.	9068	7435
63	quinidine	propranolol	10	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.	9068	8787
63	quinidine	quinidine	10	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.	9068	9068
63	ranitidine 150 mg	cimetidine 400 mg	2	1	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).	9143	2541
63	ranitidine 150 mg	nisoldipine	2	1	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).	9143	7435
65	triazolam	nefazodone	1	1	true	positive	When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold.	10767	31565
68	bisoprolol fumarate	cimetidine	1	3	true	negative	Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life.  However, initial dose modification is generally not necessary.  Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine.	19484	2541
68	bisoprolol fumarate	rifampin	1	1	true	positive	Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life.	19484	9384
68	bisoprolol fumarate	thiazide diuretics	1	3	true	negative	Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life.  However, initial dose modification is generally not necessary.  Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine.	19484	
68	bisoprolol fumarate	warfarin	4	4	true	negative	There was no effect of bisoprolol fumarate on prothrombin times in patients on stable doses of warfarin.	19484	11289
68	rifampin	cimetidine	1	3	true	negative	Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life.  However, initial dose modification is generally not necessary.  Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine.	9384	2541
68	rifampin	thiazide diuretics	1	3	true	negative	Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life.  However, initial dose modification is generally not necessary.  Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine.	9384	
76	citalopram	cimetidine	1	1	true	positive	In subjects who had received 21 days of 40 mg/day citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.	2556	2541
77	citalopram	digoxin	1	1	true	negative	In subjects who had received 21 days of 40 mg/day citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.	2556	3407
78	citalopram	pimozide	1	1	true	positive	In a controlled study, a single dose of pimozide 2 mg coadministered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.	2556	8331
78	citalopram	pimozide 2 mg	1	1	true	positive	In a controlled study, a single dose of pimozide 2 mg coadministered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.	2556	8331
78	citalopram 40 mg	pimozide	1	1	true	positive	In a controlled study, a single dose of pimozide 2 mg coadministered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.	2556	8331
78	citalopram 40 mg	pimozide 2 mg	1	1	true	positive	In a controlled study, a single dose of pimozide 2 mg coadministered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.	2556	8331
79	citalopram	warfarin	1	1	true	negative	Administration of 40 mg/day citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate.	2556	11289
80	citalopram	ketoconazole	1	1	true	positive	Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.	2556	6135
81	citalopram	metoprolol	1	1	true	positive	Administration of 40 mg/day citalopram for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol.	2556	6918
83	theophylline	tacrine	1	1	true	positive	Coadministration of tacrine with theophylline increased theophylline elimination half-life and average plasma theophylline concentrations by approximately 2-fold.	10438	10318
84	cimetidine	tacrine	1	1	true	positive	Cimetidine increased the Cmax and AUC of tacrine by approximately 54% and 64%, respectively.	2541	10318
88	phenytoin	septra	1	1	true	positive	SEPTRA may inhibit the hepatic metabolism of phenytoin.	8183	10180
91	4-hydroxyatomoxetine	quinidine	28	26	true	negative	Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].  Atomoxetine did not inhibit or induce the CYP2D6 pathway.  The major oxidative metabolite formed, regardless of CYP2D6 status, is 4-hydroxyatomoxetine, which is glucuronidated.		9068
91	atomoxetine	quinidine	8	9	true	positive	These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)].  Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.	38400	9068
91	atomoxetine hydrochloride	atomoxetine	17	17	true	positive	Administration of atomoxetine hydrochloride with a standard high-fat meal in adults did not affect the extent of oral absorption of atomoxetine (AUC), but did decrease the rate of absorption, resulting in a 37% lower Cmax, and delayed Tmax by 3 hours.	38400	38400
91	atomoxetine hydrochloride	atomoxetine hydrochloride	17	17	true	positive	Administration of atomoxetine hydrochloride with a standard high-fat meal in adults did not affect the extent of oral absorption of atomoxetine (AUC), but did decrease the rate of absorption, resulting in a 37% lower Cmax, and delayed Tmax by 3 hours.	38400	38400
91	fluoxetine	4-hydroxyatomoxetine	26	28	true	negative	Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].  Atomoxetine did not inhibit or induce the CYP2D6 pathway.  The major oxidative metabolite formed, regardless of CYP2D6 status, is 4-hydroxyatomoxetine, which is glucuronidated.	4493	
91	fluoxetine	atomoxetine	9	8	true	positive	These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)].  Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.	4493	38400
91	fluoxetine	atomoxetine hydrochloride	26	26	true	positive	Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].	4493	38400
91	n-desmethylatomoxetine	atomoxetine	35	34	true	positive	For PMs, AUC of atomoxetine is approximately 10-fold and Css,max is about 5-fold greater than EMs .  The elimination half-life of 4-hydroxyatomoxetine is similar to that of N-desmethylatomoxetine (6 to 8 hours) in EM subjects, while the half-life of N-desmethylatomoxetine is much longer in PM subjects (34 to 40 hours).		38400
91	paroxetine	4-hydroxyatomoxetine	26	28	true	negative	Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].  Atomoxetine did not inhibit or induce the CYP2D6 pathway.  The major oxidative metabolite formed, regardless of CYP2D6 status, is 4-hydroxyatomoxetine, which is glucuronidated.	32937	
91	paroxetine	atomoxetine	9	8	true	positive	These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)].  Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.	32937	38400
91	paroxetine	atomoxetine hydrochloride	26	26	true	positive	Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].	32937	38400
91	quinidine	4-hydroxyatomoxetine	26	28	true	negative	Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].  Atomoxetine did not inhibit or induce the CYP2D6 pathway.  The major oxidative metabolite formed, regardless of CYP2D6 status, is 4-hydroxyatomoxetine, which is glucuronidated.	9068	
91	quinidine	atomoxetine	9	8	true	positive	These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)].  Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.	9068	38400
91	quinidine	atomoxetine hydrochloride	26	26	true	positive	Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].	9068	38400
92	sirolimus	sirolimus	1	1	true	positive	Sirolimus (CYP3A4 substrate): Repeat dose administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 7-fold (90% CI: 5.7, 7.5) and 11-fold (90% CI: 9.9, 12.6), respectively, in healthy male subjects.	35302	35302
92	sirolimus	voriconazole	1	1	true	positive	Sirolimus (CYP3A4 substrate): Repeat dose administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 7-fold (90% CI: 5.7, 7.5) and 11-fold (90% CI: 9.9, 12.6), respectively, in healthy male subjects.	35302	121243
94	alprazolam	erythromycin	1	2	true	positive	Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations.  Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ).	596	4053
94	alprazolam	itraconazole	1	2	true	positive	Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations.  Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ).	596	28031
94	alprazolam	ketoconazole	1	2	true	positive	Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations.  Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ).	596	6135
94	fluvoxamine	alprazolam	2	1	true	positive	Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations.  Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ).	42355	596
94	fluvoxamine	nefazodone	2	2	true	positive	Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ).	42355	31565
94	nefazodone	alprazolam	2	1	true	positive	Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations.  Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ).	31565	596
94	nefazodone	erythromycin	2	2	true	positive	Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ).	31565	4053
95	alprazolam	nefazodone	1	1	true	positive	Coadministration of nefazodone increased alprazolam concentration two-fold.	596	31565
96	alprazolam	fluvoxamine	1	1	true	positive	Coadministration of fluvoxamine approximately doubled the maximum plasma concentration of alprazolam, decreased clearance by 49%, increased half-life by 71%, and decreased measured psychomotor performance.	596	42355
97	alprazolam	cimetidine	1	1	true	positive	Coadministration of cimetidine increased the maximum plasma concentration of alprazolam by 86%, decreased clearance by 42%, and increased half-life by 16%.	596	2541
99	alprazolam	propoxyphene	1	1	true	positive	Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.	596	8785
100	alprazolam	carbamazepine	1	1	true	positive	Drugs demonstrated to be inducers of CYP3A     Carbamazepine can increase alprazolam metabolism and therefore can decrease plasma levels of alprazolam.	596	2002
105	conivaptan	conivaptan	34	34	true	positive	However, following administration of oral conivaptan in patients with renal impairment (CLcr 30 - 60 mL/min or CLcr 10 - 29 mL/min), the AUCs for conivaptan were 70% and 85% higher, respectively, compared to patients with normal renal function.	302285	302285
105	conivaptan hydrochloride	conivaptan	16	14	true	negative	The pharmacokinetics of conivaptan following intravenous infusion (40 mg/day to 80 mg/day) and oral administration are non-linear, and inhibition by conivaptan of its own metabolism seems to be the major factor for the non-linearity.  The intersubject variability of conivaptan pharmacokinetics is high (94% CV in CL).  The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.	302285	302285
107	metoprolol succinate	metoprolol	33	31	true	positive	Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%.  The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.	6918	6918
108	nifedipine	quinidine	2	1	true	positive	Quinidine:  Quinidine is a substrate of CYP3A and has been shown to inhibit CYP3A in vitro.  Coadministration of multiple doses of quinidine sulfate, 200 mg t.i.d., and nifedipine, 20 mg t.i.d., increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37, respectively.	7417	9068
108	nifedipine	quinidine sulfate	2	2	true	positive	Coadministration of multiple doses of quinidine sulfate, 200 mg t.i.d., and nifedipine, 20 mg t.i.d., increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37, respectively.	7417	9068
108	quinidine sulfate	quinidine	2	1	true	positive	Quinidine:  Quinidine is a substrate of CYP3A and has been shown to inhibit CYP3A in vitro.  Coadministration of multiple doses of quinidine sulfate, 200 mg t.i.d., and nifedipine, 20 mg t.i.d., increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37, respectively.	9068	9068
109	diltiazem	diltiazem	1	1	true	positive	Diltiazem:  Pretreatment of healthy volunteers with 30 mg or 90 mg t.i.d. diltiazem p.o. increased the AUC of nifedipine after a single dose of 20 mg nifedipine by factors of 2.2 and 3.1, respectively.	3443	3443
109	nifedipine	diltiazem	1	1	true	positive	Diltiazem:  Pretreatment of healthy volunteers with 30 mg or 90 mg t.i.d. diltiazem p.o. increased the AUC of nifedipine after a single dose of 20 mg nifedipine by factors of 2.2 and 3.1, respectively.	7417	3443
111	doxazosin	doxazosin	1	1	true	positive	Doxazosin:  Healthy volunteers participating in a multiple dose doxazosin-nifedipine interaction study received 2 mg doxazosin q.d. alone or combined with 20 mg nifedipine ER b.i.d. Coadministration of nifedipine resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively.	49276	49276
111	nifedipine	doxazosin	1	1	true	positive	Doxazosin:  Healthy volunteers participating in a multiple dose doxazosin-nifedipine interaction study received 2 mg doxazosin q.d. alone or combined with 20 mg nifedipine ER b.i.d. Coadministration of nifedipine resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively.	7417	49276
112	nifedipine	clopidogrel	1	1	true	negative	Clopidogrel: No clinically significant pharmacodynamic interactions were observed when clopidrogrel was coadministered with nifedipine.	7417	32968
113	cimetidine	cimetidine	1	1	true	negative	Cimetidine: Five studies in healthy volunteers investigated the impact of multiple cimetidine doses on the single or multiple dose pharmacokinetics of nifedipine.	2541	2541
113	nifedipine	cimetidine	1	1	true	negative	Cimetidine: Five studies in healthy volunteers investigated the impact of multiple cimetidine doses on the single or multiple dose pharmacokinetics of nifedipine.	7417	2541
114	dalfopristin	dalfopristin	1	1	true	positive	Quinupristin/Dalfopristin:In vitro drug interaction studies have demonstrated that quinupristin/dalfopristin significantly inhibits the CYP3A metabolism of nifedipine.	229369	229369
114	nifedipine	dalfopristin	1	1	true	positive	Quinupristin/Dalfopristin:In vitro drug interaction studies have demonstrated that quinupristin/dalfopristin significantly inhibits the CYP3A metabolism of nifedipine.	7417	229369
114	quinupristin	dalfopristin	1	1	true	positive	Quinupristin/Dalfopristin:In vitro drug interaction studies have demonstrated that quinupristin/dalfopristin significantly inhibits the CYP3A metabolism of nifedipine.	229367	229369
114	quinupristin	nifedipine	1	1	true	positive	Quinupristin/Dalfopristin:In vitro drug interaction studies have demonstrated that quinupristin/dalfopristin significantly inhibits the CYP3A metabolism of nifedipine.	229367	7417
114	quinupristin	quinupristin	1	1	true	positive	Quinupristin/Dalfopristin:In vitro drug interaction studies have demonstrated that quinupristin/dalfopristin significantly inhibits the CYP3A metabolism of nifedipine.	229367	229367
115	nifedipine 10 mg	nifedipine	2	1	true	positive	Phenytoin: Nifedipine is metabolized by CYP3A4.  Coadministration of nifedipine 10 mg capsule and 60 mg nifedipine coat-core tablet with phenytoin, an inducer of CYP3A4, lowered the AUC and Cmax of nifedipine by approximately 70%.	7417	7417
115	phenytoin	nifedipine 10 mg	1	2	true	positive	Phenytoin: Nifedipine is metabolized by CYP3A4.  Coadministration of nifedipine 10 mg capsule and 60 mg nifedipine coat-core tablet with phenytoin, an inducer of CYP3A4, lowered the AUC and Cmax of nifedipine by approximately 70%.	8183	7417
116	rosiglitazone	nifedipine	1	1	true	negative	Rosiglitazone:  Coadministration of rosiglitazone (4 mg b.i.d.) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine.	84108	7417
116	rosiglitazone	rosiglitazone	1	1	true	negative	Rosiglitazone:  Coadministration of rosiglitazone (4 mg b.i.d.) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine.	84108	84108
118	midazolam	synercid	1	1	true	positive	Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs.	6960	229369
118	nifedipine	midazolam	1	1	true	positive	Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs.	7417	6960
118	nifedipine	synercid	1	1	true	positive	Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs.	7417	229369
120	metronidazole	coumarin	1	1	true	positive	Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time.	6922	2898
120	metronidazole	warfarin	1	1	true	positive	Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time.	6922	11289
123	acarbose	glimepiride	73	71	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.	16681	25789
123	acarbose	rosiglitazone	73	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.	16681	84108
123	avandia	acarbose	71	73	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.	84108	16681
123	avandia	insulin	13	11	true	negative	The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.	84108	5856
123	digoxin	acarbose	74	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.	3407	16681
123	digoxin	avandia	74	76	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.	3407	84108
123	digoxin	digoxin	74	74	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.	3407	3407
123	digoxin	ethanol	74	76	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.	3407	448
123	digoxin	rosiglitazone	74	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.	3407	84108
123	ethanol	rosiglitazone	76	77	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.	448	84108
123	ethinyl estradiol	avandia	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.	4124	84108
123	ethinyl estradiol	gemfibrozil	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.	4124	4719
123	ethinyl estradiol	norethindrone	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.	4124	7514
123	ethinyl estradiol	rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.	4124	84108
123	gemfibrozil	avandia	65	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.	4719	84108
123	gemfibrozil	gemfibrozil	65	65	true	positive	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.	4719	4719
123	glimepiride	acarbose	71	73	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.	25789	16681
123	glimepiride	metformin	70	72	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.	25789	6809
123	glyburide	avandia	68	68	true	positive	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.	4815	84108
123	glyburide	glyburide	68	68	true	positive	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.	4815	4815
123	metformin	acarbose	72	73	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.	6809	16681
123	metformin	avandia	72	70	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.	6809	84108
123	metformin	digoxin	72	74	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.	6809	3407
123	metformin	glimepiride	72	70	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.	6809	25789
123	metformin	metformin	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.	6809	6809
123	nifedipine	avandia	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.	7417	84108
123	nifedipine	ethinyl estradiol	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.	7417	4124
123	nifedipine	gemfibrozil	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.	7417	4719
123	nifedipine	norethindrone	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.	7417	7514
123	nifedipine	rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.	7417	84108
123	norethindrone	avandia	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.	7514	84108
123	norethindrone	gemfibrozil	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.	7514	4719
123	norethindrone	rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.	7514	84108
123	ranitidine	avandia	77	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.	9143	84108
123	ranitidine	ethanol	77	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.	9143	448
123	ranitidine	ranitidine	77	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.	9143	9143
123	rifampin	avandia	67	68	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.	9384	84108
123	rifampin	glyburide	67	68	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.	9384	4815
123	rosiglitazone	acarbose	72	73	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.	84108	16681
123	rosiglitazone	avandia	65	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.	84108	84108
123	rosiglitazone	digoxin	72	74	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.	84108	3407
123	rosiglitazone	ethanol	77	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.	84108	448
123	rosiglitazone	gemfibrozil	65	65	true	positive	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.	84108	4719
123	rosiglitazone	glimepiride	72	70	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.	84108	25789
123	rosiglitazone	metformin	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.	84108	6809
123	rosiglitazone	ranitidine	77	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.	84108	9143
123	warfarin	acarbose	75	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.	11289	16681
123	warfarin	digoxin	75	74	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.	11289	3407
123	warfarin	ranitidine	75	77	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.	11289	9143
123	warfarin	rosiglitazone	75	77	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.	11289	84108
124	propafenone	propranolol	1	1	true	positive	The AUC of propafenone is increased by more than 200% by co-administration of propranolol.	8754	8787
125	quinidine	propranolol	1	1	true	positive	The metabolism of propranolol is reduced by co-administration of quinidine, leading to a two-three fold increased blood concentration and greater degrees of clinical beta-blockade.	9068	8787
126	nifedipine	propranolol	1	1	true	positive	The mean Cmax and AUC of nifedipine are increased by 64% and 79%, respectively, by co-administration of propranolol.	7417	8787
127	norverapamil	propranolol	1	1	true	negative	Propranolol does not affect the pharmacokinetics of verapamil and norverapamil.		8787
127	propranolol	propranolol	1	1	true	negative	Propranolol does not affect the pharmacokinetics of verapamil and norverapamil.	8787	8787
127	verapamil	norverapamil	1	1	true	negative	Propranolol does not affect the pharmacokinetics of verapamil and norverapamil.	11170	
127	verapamil	propranolol	1	1	true	negative	Propranolol does not affect the pharmacokinetics of verapamil and norverapamil.	11170	8787
127	verapamil	verapamil	1	1	true	negative	Propranolol does not affect the pharmacokinetics of verapamil and norverapamil.	11170	11170
128	diazepam	diazepam	1	1	true	positive	Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites.	3322	3322
128	propranolol	diazepam	1	1	true	positive	Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites.	8787	3322
128	propranolol	propranolol	1	1	true	positive	Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites.	8787	8787
130	propranolol	metoclopramide	1	1	true	negative	Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolol’s pharmacokinetics.	8787	6915
131	cholestyramine	colestipol	1	1	true	positive	Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations.	2447	2685
131	cholestyramine	propranolol	1	1	true	positive	Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations.	2447	8787
131	colestipol	propranolol	1	1	true	positive	Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations.	2685	8787
132	fluvastatin	lovastatin	2	1	true	negative	Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.  Propranolol did not have an effect on the pharmacokinetics of fluvastatin.	41127	6472
132	fluvastatin	propranolol	2	1	true	negative	Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.  Propranolol did not have an effect on the pharmacokinetics of fluvastatin.	41127	8787
132	pravastatin	fluvastatin	1	2	true	negative	Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.  Propranolol did not have an effect on the pharmacokinetics of fluvastatin.	42463	41127
132	pravastatin	lovastatin	1	1	true	positive	Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.	42463	6472
132	pravastatin	propranolol	1	1	true	positive	Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.	42463	8787
132	propranolol	lovastatin	1	1	true	positive	Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.	8787	6472
132	propranolol	propranolol	1	1	true	positive	Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.	8787	8787
133	mesoridazine	propranolol	1	1	true	positive	Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%.	6779	8787
133	thioridazine	mesoridazine	1	1	true	positive	Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%.	10502	6779
133	thioridazine	propranolol	1	1	true	positive	Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%.	10502	8787
134	propranolol	chlorpromazine	1	1	true	positive	Co-administration of chlorpromazine with propranolol resulted in a 70% increase in propranolol plasma level.	8787	2403
136	indinavir	trazodone	1	1	true	positive	In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir.	114289	10737
136	ketoconazole	trazodone	1	1	true	positive	In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir.	6135	10737
136	ritonavir	trazodone	1	1	true	positive	In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir.	85762	10737
137	carbamazepine	trazodone	1	2	true	positive	Carbamazepine induces CYP3A4.  Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.	2002	10737
137	carbamazepine 400 mg	carbamazepine	2	1	true	positive	Carbamazepine induces CYP3A4.  Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.	2002	2002
137	carbamazepine 400 mg	trazodone	2	2	true	positive	Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.	2002	10737
139	erythromycin	fexofenadine hydrochloride	4	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.	4053	87636
139	fexofenadine	erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.	87636	4053
139	fexofenadine	fexofenadine hydrochloride 120 mg	6	8	true	negative	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).	87636	87636
139	fexofenadine hydrochloride	erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.	87636	4053
139	fexofenadine hydrochloride	fexofenadine	17	15	true	positive	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.	87636	87636
139	fexofenadine hydrochloride 120 mg	fexofenadine hydrochloride	8	6	true	negative	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).	87636	87636
139	ketoconazole	fexofenadine	4	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.	6135	87636
139	ketoconazole	fexofenadine hydrochloride	4	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.	6135	87636
139	maalox	erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.		4053
139	maalox	ketoconazole	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.		6135
140	fexofenadine hydrochloride	fexofenadine hydrochloride	35	35	true	negative	Hepatically Impaired    The pharmacokinetics of fexofenadine hydrochloride in subjects with hepatic impairment did not differ substantially from that observed in healthy subjects.	87636	87636
140	glycoprotein	fexofenadine hydrochloride	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.		87636
145	felbamate	valproate	2	1	true	negative	Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol® at steady-state.  Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol® (felbamate) plasma concentrations.	24812	40254
145	valproate	felbatol	1	1	true	negative	Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol® at steady-state.	40254	24812
145	valproate	valproate	1	1	true	negative	Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol® at steady-state.	40254	40254
147	felbamate	felbatol	3	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.	24812	24812
147	felbamate	phenytoin	3	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.	24812	8183
147	phenytoin	felbatol	1	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.	8183	24812
147	phenytoin	phenytoin	1	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.	8183	8183
148	carbamazepine	carbamazepine	1	1	true	positive	Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.	2002	2002
148	carbamazepine	felbamate	1	3	true	positive	Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.  In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8±2 micrograms/mL.  The carbamazepine steady-state Cmin decreased 31% to 5±1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.	2002	24812
148	carbamazepine epoxide	carbamazepine	1	1	true	positive	Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.		2002
148	carbamazepine epoxide	carbamazepine epoxide	1	1	true	positive	Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.		
148	carbamazepine epoxide	felbatol	1	1	true	positive	Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.		24812
148	felbamate	carbamazepine	3	1	true	positive	Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.  In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8±2 micrograms/mL.  The carbamazepine steady-state Cmin decreased 31% to 5±1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.	24812	2002
148	felbamate	carbamazepine epoxide	3	1	true	positive	Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.  In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8±2 micrograms/mL.  The carbamazepine steady-state Cmin decreased 31% to 5±1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.	24812	
148	felbatol	carbamazepine	1	1	true	positive	Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.	24812	2002
148	felbatol	carbamazepine epoxide	1	1	true	positive	Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.	24812	
148	felbatol	felbamate	1	3	true	positive	Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.  In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8±2 micrograms/mL.  The carbamazepine steady-state Cmin decreased 31% to 5±1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.	24812	24812
149	felbamate	felbatol	3	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.	24812	24812
149	felbamate	valproate	3	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.	24812	40254
149	valproate	felbatol	1	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.	40254	24812
149	valproate	valproate	1	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.	40254	40254
150	felbamate	phenobarbital	1	1	true	positive	Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations.	24812	8134
150	phenobarbital	phenobarbital	1	1	true	positive	Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations.	8134	8134
151	felbamate	felbatol	1	1	true	positive	Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol® (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy.	24812	24812
151	felbamate	phenytoin	1	1	true	positive	Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol® (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy.	24812	8183
151	phenytoin	felbatol	1	1	true	positive	Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol® (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy.	8183	24812
151	phenytoin	phenytoin	1	1	true	positive	Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol® (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy.	8183	8183
152	carbamazepine	carbamazepine	1	1	true	positive	Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol® at steady-state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy.	2002	2002
152	felbatol	carbamazepine	1	1	true	positive	Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol® at steady-state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy.	24812	2002
155	a 300	a 10	54	54	true	positive	Ritonavir and other CYP3A Inhibitors    In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.		
155	bosentan	bosentan	65	65	true	positive	Bosentan    In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax.	75207	75207
155	epoprostenol	sildenafil	69	68	true	positive	Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil.  Epoprostenol    The mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations.	8814	136411
155	revatio	bosentan	64	65	true	positive	REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration.  Bosentan    In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax.	136411	75207
155	ritonavir	a 10	54	54	true	positive	Ritonavir and other CYP3A Inhibitors    In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.	85762	
155	ritonavir	a 300	54	54	true	positive	Ritonavir and other CYP3A Inhibitors    In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.	85762	
155	ritonavir	ritonavir	54	54	true	positive	Ritonavir and other CYP3A Inhibitors    In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.	85762	85762
155	ritonavir	sildenafil	54	55	true	positive	Ritonavir and other CYP3A Inhibitors    In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.  At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone.	85762	136411
155	sildenafil	a 10	35	37	true	positive	After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of the administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose).  REVATIO Injection: The pharmacokinetic profile of REVATIO has been characterized following intravenous administration.  A 10 mg dose of REVATIO Injection is predicted to provide a pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose.	136411	
155	sildenafil	a 300	55	54	true	positive	Ritonavir and other CYP3A Inhibitors    In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.  At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone.	136411	
155	sildenafil	epoprostenol	68	69	true	positive	Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil.  Epoprostenol    The mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations.	136411	8814
156	aliskiren	aliskiren	1	1	true	positive	7  DRUG INTERACTIONS    7.1 Effects of Other Drugs on Aliskiren    Based on in vitro studies, aliskiren is metabolized by CYP 3A4.	325646	325646
156	aliskiren	atenolol	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.	325646	1202
156	aliskiren	celecoxib	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.	325646	140587
156	aliskiren	digoxin	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.	325646	3407
156	aliskiren	hydrochlorothiazide	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.	325646	5487
156	aliskiren	itraconazole	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.	325646	28031
156	aliskiren	lovastatin	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.	325646	6472
156	aliskiren	ramipril	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.	325646	35296
156	aliskiren	warfarin	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.	325646	11289
156	amlodipine	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.	17767	325646
156	atenolol	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.	1202	325646
156	atorvastatin	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.	83367	325646
156	celecoxib	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.	140587	325646
156	cyclosporine	cyclosporine	10	10	true	positive	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.	3008	3008
156	digoxin	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.	3407	325646
156	furosemide	aliskiren	17	15	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.	4603	325646
156	irbesartan	irbesartan	2	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.	83818	83818
156	itraconazole	aliskiren	8	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.	28031	325646
156	itraconazole	itraconazole	8	8	true	positive	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.	28031	28031
156	ketoconazole	aliskiren	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.	6135	325646
156	ketoconazole	atorvastatin	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.	6135	83367
156	ketoconazole	itraconazole	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.	6135	28031
156	ketoconazole	ketoconazole	6	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.	6135	6135
156	lovastatin	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.	6472	325646
156	metformin	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.	6809	325646
156	ramipril	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.	35296	325646
156	verapamil	verapamil	12	12	true	positive	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.	11170	11170
156	warfarin	aliskiren	19	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.	11289	325646
156	warfarin	warfarin	19	19	true	negative	Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.	11289	11289
157	angiotensinogen	aliskiren	9	9	true	positive	Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known.		325646
158	fluvoxamine	mexiletine	2	1	true	positive	Since mexiletine is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations.  In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.	42355	6926
158	fluvoxamine	propafenone	2	3	true	negative	In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.  In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group.	42355	8754
158	propafenone	mexiletine	3	1	true	negative	Since mexiletine is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations.  In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.  In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group.	8754	6926
159	digoxin	mexiletine	1	1	true	negative	Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels.	3407	6926
159	digoxin	mexiletine hydrochloride	1	1	true	negative	Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels.	3407	6926
161	azithromycin	nelfinavir	1	1	true	positive	Coadministration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations.	18631	134527
163	acyclovir	acyclovir	1	1	true	positive	Acyclovir    Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration.	281	281
163	meperidine	acyclovir	1	1	true	positive	Acyclovir    Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration.	6754	281
163	meperidine	normeperidine	1	1	true	positive	Acyclovir    Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration.	6754	
163	normeperidine	acyclovir	1	1	true	positive	Acyclovir    Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration.		281
164	meperidine	cimetidine	1	1	true	positive	Cimetidine    Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration.	6754	2541
164	meperidine	normeperidine	1	1	true	positive	Cimetidine    Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration.	6754	
164	normeperidine	cimetidine	1	1	true	positive	Cimetidine    Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration.		2541
166	methotrexate	penicillins	1	1	true	positive	Penicillins may reduce the renal clearance of methotrexate; increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with methotrexate.	6851	
168	clonazepam	carbamazepine	1	1	true	negative	Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital.	2598	2002
168	clonazepam	phenobarbital	1	1	true	negative	Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital.	2598	8134
168	phenytoin	clonazepam	1	1	true	negative	Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital.	8183	2598
172	atorvastatin	atorvastatin	17	17	true	positive	Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.	83367	83367
172	atorvastatin	cyclosporine	17	15	true	positive	In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg [see Warnings and Precautions, Skeletal Muscle (5.1)].  7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.	83367	3008
172	atorvastatin	efavirenz	17	16	true	positive	7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.	83367	195085
172	atorvastatin	lopinavir	5	7	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].	83367	195088
172	atorvastatin	rifampin	17	17	true	positive	Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.	83367	9384
172	clarithromycin	lopinavir	5	7	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].	21212	195088
172	cyclosporine	efavirenz	14	16	true	positive	Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg [see Warnings and Precautions, Skeletal Muscle (5.1)].  7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.	3008	195085
172	digoxin	atorvastatin	19	17	true	positive	Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.  7.5 Digoxin    When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.  Patients taking digoxin should be monitored appropriately.	3407	83367
172	digoxin	efavirenz	18	16	true	positive	7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.  7.5 Digoxin    When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.	3407	195085
172	efavirenz	atorvastatin	16	17	true	positive	7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.	195085	83367
172	itraconazole	lopinavir	9	7	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].	28031	195088
172	itraconazole	ritonavir	9	7	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].	28031	85762
172	itraconazole 200 mg	atorvastatin	9	7	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].	28031	83367
172	itraconazole 200 mg	itraconazole	9	9	true	positive	Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].	28031	28031
172	itraconazole 200 mg	lipitor	9	7	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].	28031	83367
172	itraconazole 200 mg	lopinavir	9	7	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].	28031	195088
172	itraconazole 200 mg	ritonavir	9	7	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].	28031	85762
172	itraconazole 200 mg	saquinavir	9	7	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].	28031	83395
172	lipitor	atorvastatin	2	3	true	positive	7.1 Strong Inhibitors of CYP 3A4    LIPITOR is metabolized by cytochrome P450 3A4.  Concomitant administration of LIPITOR with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin.	83367	83367
172	lipitor	digoxin	17	19	true	positive	Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.  7.5 Digoxin    When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.  Patients taking digoxin should be monitored appropriately.	83367	3407
172	lipitor	efavirenz	14	16	true	positive	Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg [see Warnings and Precautions, Skeletal Muscle (5.1)].  7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.	83367	195085
172	lipitor	lopinavir	5	7	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].	83367	195088
172	lipitor	rifampin	14	16	true	positive	Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg [see Warnings and Precautions, Skeletal Muscle (5.1)].  7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.	83367	9384
172	lipitor	ritonavir	5	7	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].	83367	85762
172	lipitor	saquinavir	5	7	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].	83367	83395
172	rifampin	atorvastatin	17	17	true	positive	Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.	9384	83367
172	rifampin	cyclosporine	17	15	true	positive	In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg [see Warnings and Precautions, Skeletal Muscle (5.1)].  7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.	9384	3008
172	rifampin	digoxin	17	19	true	positive	Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.  7.5 Digoxin    When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.  Patients taking digoxin should be monitored appropriately.	9384	3407
172	rifampin	efavirenz	17	16	true	positive	7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.	9384	195085
172	rifampin	rifampin	17	17	true	positive	Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.	9384	9384
172	ritonavir	atorvastatin	7	5	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].	85762	83367
172	ritonavir	clarithromycin	7	5	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].	85762	21212
172	ritonavir	lopinavir	7	7	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].	85762	195088
172	saquinavir	atorvastatin	7	5	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].	83395	83367
172	saquinavir	clarithromycin	7	5	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].	83395	21212
172	saquinavir	itraconazole	7	9	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].	83395	28031
172	saquinavir	lopinavir	7	7	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].	83395	195088
172	saquinavir	ritonavir	7	7	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].	83395	85762
173	cholesterol	cholesterol	16	16	true	positive	Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including VLDL, intermediate density lipoprotein (IDL), and remnants, can also promote atherosclerosis.	2438	2438
174	rifampin	tacrolimus	1	1	true	positive	In a study of 6 normal volunteers, a significant decrease in tacrolimus oral bioavailability (14±6% vs. 7±3%) was observed with concomitant rifampin administration (600 mg).	9384	42316
175	nelfinavir	tacrolimus	2	2	true	positive	However, care should be exercised when drugs that are nephrotoxic (e.g., ganciclovir) or that are metabolized by CYP3A (e.g., nelfinavir, ritonavir) are administered concomitantly with tacrolimus.	134527	42316
175	phenytoin	tacrolimus	5	3	true	positive	Based on a clinical study of 5 liver transplant recipients, coadministration of tacrolimus with nelfinavir increased blood concentrations of tacrolimus significantly and, as a result, a reduction in the tacrolimus dose by an average of 16-fold was needed to maintain mean trough tacrolimus blood concentrations of 9.7 ng/mL.  Thus, frequent monitoring of tacrolimus blood concentrations and appropriate dosage adjustments are essential when nelfinavir is used concomitantly.  Tacrolimus may affect the pharmacokinetics of other drugs (e.g., phenytoin) and increase their concentration.	8183	42316
175	ritonavir	tacrolimus	2	2	true	positive	However, care should be exercised when drugs that are nephrotoxic (e.g., ganciclovir) or that are metabolized by CYP3A (e.g., nelfinavir, ritonavir) are administered concomitantly with tacrolimus.	85762	42316
175	tacrolimus	ganciclovir	2	2	true	positive	However, care should be exercised when drugs that are nephrotoxic (e.g., ganciclovir) or that are metabolized by CYP3A (e.g., nelfinavir, ritonavir) are administered concomitantly with tacrolimus.	42316	4678
177	diazepam	cimetidine	1	3	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).  Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.  At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.	3322	2541
177	diazepam	fluoxetine	1	3	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).  Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.  At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.	3322	4493
177	diazepam	fluvoxamine	1	3	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).  Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.  At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.	3322	42355
177	diazepam	ketoconazole	1	3	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).  Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.  At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.	3322	6135
177	diazepam	omeprazole	1	3	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).  Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.  At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.	3322	7646
181	adriamycin	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.	3639	56946
181	antineoplastic agents	paclitaxel	31	33	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.		56946
181	cimetidine	theophylline	60	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.	2541	10438
181	cisplatin	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.	2555	56946
181	cyclophosphamide	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.	3002	56946
181	digitoxin	digitalis	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.	3403	
181	digitoxin	digoxin	24	23	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.	3403	3407
181	digitoxin	verapamil	24	23	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.	3403	11170
181	paclitaxel	doxorubicin	33	31	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.	56946	3639
181	paclitaxel	oncovin	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.	56946	
181	paclitaxel	procarbazine	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.	56946	8702
181	prazosin	flecainide	43	45	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.	8629	4441
181	prazosin	verapamil	43	42	true	positive	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.	8629	11170
181	prednisone	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.	8640	56946
181	quinidine	paclitaxel	34	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.	9068	56946
181	rifampin	cimetidine	58	60	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.	9384	2541
181	theophylline	cimetidine	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.	10438	2541
181	theophylline	phenobarbital	59	57	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.	10438	8134
181	theophylline	rifampin	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.	10438	9384
181	theophylline	theophylline	59	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.	10438	10438
181	verapamil	cimetidine	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.	11170	2541
181	verapamil	flecainide	43	45	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.	11170	4441
181	verapamil	norverapamil	8	10	true	negative	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.	11170	
181	verapamil	paclitaxel	31	33	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.	11170	56946
181	verapamil	theophylline	59	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.	11170	10438
181	vindesine	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.	11204	56946
182	basis	verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.	10795	11170
182	norverapamil	norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.		
182	norverapamil	verapamil hydrochloride	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.		11170
182	procaine	verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.	8701	11170
182	verapamil hydrochloride	norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.	11170	
182	verapamil hydrochloride	verapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.	11170	11170
183	theophylline	amoxicillin	10	12	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.	10438	723
183	theophylline	clarithromycin	10	12	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.	10438	21212
183	theophylline	tacrolimus	10	9	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.	10438	42316
183	theophylline	theophylline	10	10	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.	10438	10438
183	warfarin	tacrolimus	8	9	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.	11289	42316
183	warfarin	theophylline	8	10	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.	11289	10438
183	warfarin	warfarin	5	5	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).	11289	11289
184	7-hydroxymethotrexate	naproxen 500 mg	104	104	true	negative	Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.		7258
184	amoxicillin	7-hydroxymethotrexate	106	104	true	negative	Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.  While this study was not designed to assess the safety of this combination of drugs, no major adverse reactions were noted.  Amoxicillin: Lansoprazole delayed-release capsules has also been shown to have no clinically significant interaction with amoxicillin.	723	
184	amoxicillin	naproxen 500 mg	106	104	true	negative	Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.  While this study was not designed to assess the safety of this combination of drugs, no major adverse reactions were noted.  Amoxicillin: Lansoprazole delayed-release capsules has also been shown to have no clinically significant interaction with amoxicillin.	723	7258
184	methotrexate	7-hydroxymethotrexate	104	104	true	negative	Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.	6851	
184	methotrexate	amoxicillin	104	106	true	negative	Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.  While this study was not designed to assess the safety of this combination of drugs, no major adverse reactions were noted.  Amoxicillin: Lansoprazole delayed-release capsules has also been shown to have no clinically significant interaction with amoxicillin.	6851	723
184	methotrexate	methotrexate	104	104	true	negative	Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.	6851	6851
184	methotrexate	naproxen 500 mg	104	104	true	negative	Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.	6851	7258
184	omeprazole 20 mg	amoxicillin	107	106	true	positive	Amoxicillin: Lansoprazole delayed-release capsules has also been shown to have no clinically significant interaction with amoxicillin.  Sucralfate: In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.	7646	723
184	theophylline	atazanavir	98	96	true	positive	Therefore, lansoprazole delayed-release capsules, or other proton pump inhibitors, should not be co-administered with atazanavir.  Theophylline: When lansoprazole delayed-release capsules were administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.  Because of the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be of clinical concern.	10438	343047
184	warfarin	7-hydroxymethotrexate	103	104	true	negative	Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.	11289	
184	warfarin	methotrexate	103	104	true	negative	Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.	11289	6851
184	warfarin	naproxen 500 mg	103	104	true	negative	Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.	11289	7258
186	cyclosporine	simvastatin	21	22	true	positive	Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.  The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.	3008	36567
186	cyclosporine	simvastatin acid	21	22	true	positive	Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.  The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.	3008	
186	hmg-coa	simvastatin 40 mg	18	18	true	positive	In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.		36567
186	simvastatin 40 mg	simvastatin	18	17	true	positive	Relative to the fasting state, the plasma profile of inhibitors was not affected when simvastatin was administered immediately before an American Heart Association recommended low-fat meal.  In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.	36567	36567
187	acetaminophen	reyataz	20	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.	161	343047
187	desipramine	metoprolol	19	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).	3247	6918
187	fluvastatin	reyataz	18	19	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).	41127	343047
187	methadone	reyataz	20	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.	6813	343047
187	nortriptyline	metoprolol	19	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).	7531	6918
187	nortriptyline	reyataz	19	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).	7531	343047
187	paclitaxel	reyataz	5	3	true	positive	Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).	56946	343047
187	paclitaxel	ritonavir	5	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).	56946	85762
187	pravastatin	reyataz	18	19	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).	42463	343047
187	repaglinide	reyataz	5	3	true	positive	Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).	73044	343047
187	reyataz	atenolol	19	20	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.	343047	1202
187	reyataz	azithromycin	19	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).	343047	18631
187	reyataz	dapsone	19	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).	343047	3108
187	reyataz	desipramine	19	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).	343047	3247
187	reyataz	erythromycin	19	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).	343047	4053
187	reyataz	fluconazole	19	20	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.	343047	4450
187	ritonavir	repaglinide	5	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).	85762	73044
188	atazanavir	atazanavir sulfate	23	23	true	positive	Administration of REYATAZ (atazanavir sulfate) with either a light meal or high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately one half compared to the fasting state.	343047	343047
188	atazanavir sulfate	reyataz	23	21	true	positive	Administration of a single 400-mg dose of REYATAZ with a light meal (357 kcal, 8.2 g fat, 10.6 g protein) resulted in a 70% increase in AUC and 57% increase in Cmax relative to the fasting state.  Administration of a single 400-mg dose of REYATAZ with a high-fat meal (721 kcal, 37.3 g fat, 29.4 g protein) resulted in a mean increase in AUC of 35% with no change in Cmax relative to the fasting state.  Administration of REYATAZ (atazanavir sulfate) with either a light meal or high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately one half compared to the fasting state.	343047	343047
191	itraconazole	fluvastatin	1	1	true	negative	Itraconazole:    Concomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels.	28031	41127
191	itraconazole	itraconazole	1	1	true	negative	Itraconazole:    Concomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels.	28031	28031
192	fluvastatin	erythromycin	1	1	true	negative	Erythromycin:    Erythromycin (500 mg, single dose) did not affect steady-state plasma levels of fluvastatin (40 mg daily).	41127	4053
194	amiodarone	amiodarone	4	4	true	positive	Amiodarone    Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.	703	703
194	amiodarone	fluoxetine	4	6	true	positive	Amiodarone    Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.  Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.  Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.	703	4493
194	cimetidine	amiodarone	5	4	true	positive	Amiodarone    Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.  Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.	2541	703
194	cimetidine	cimetidine	5	5	true	positive	Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.	2541	2541
194	cimetidine	propafenone	5	4	true	positive	Amiodarone    Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.  Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.	2541	8754
194	digoxin	digoxin	17	17	true	positive	7.2 Digoxin    Concomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%.	3407	3407
194	fluoxetine	amiodarone	6	4	true	positive	Amiodarone    Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.  Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.  Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.	4493	703
194	fluoxetine	cimetidine	6	5	true	positive	Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.  Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.	4493	2541
194	fluoxetine	fluoxetine	6	6	true	positive	Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.	4493	4493
194	fluoxetine	propafenone	6	4	true	positive	Amiodarone    Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.  Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.  Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.	4493	8754
194	orlistat	metoprolol	22	24	true	positive	In post marketing reports, abrupt cessation of orlistat in patients stabilized on propafenone has resulted in severe adverse events including convulsions, atrioventricular block and acute circulatory failure.  7.5 Beta-Antagonists    Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%.  In 4 patients, administration of metoprolol with propafenone increased the metoprolol plasma concentrations at steady state by 100-400%.	37925	6918
194	orlistat	propafenone	21	19	true	positive	7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.  Adjust the warfarin dose as needed by monitoring INR (international normalized ratio).  7.4 Orlistat    Orlistat may limit the fraction of propafenone available for absorption.	37925	8754
194	propafenone	cimetidine	4	5	true	positive	Amiodarone    Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.  Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.	8754	2541
194	propafenone	metoprolol	23	25	true	positive	7.5 Beta-Antagonists    Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%.  In 4 patients, administration of metoprolol with propafenone increased the metoprolol plasma concentrations at steady state by 100-400%.  The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol.	8754	6918
194	propranolol	metoprolol	23	25	true	positive	7.5 Beta-Antagonists    Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%.  In 4 patients, administration of metoprolol with propafenone increased the metoprolol plasma concentrations at steady state by 100-400%.  The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol.	8787	6918
194	propranolol	orlistat	23	21	true	positive	7.4 Orlistat    Orlistat may limit the fraction of propafenone available for absorption.  In post marketing reports, abrupt cessation of orlistat in patients stabilized on propafenone has resulted in severe adverse events including convulsions, atrioventricular block and acute circulatory failure.  7.5 Beta-Antagonists    Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%.	8787	37925
194	propranolol	propafenone	23	21	true	positive	7.4 Orlistat    Orlistat may limit the fraction of propafenone available for absorption.  In post marketing reports, abrupt cessation of orlistat in patients stabilized on propafenone has resulted in severe adverse events including convulsions, atrioventricular block and acute circulatory failure.  7.5 Beta-Antagonists    Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%.	8787	8754
194	quinidine	cimetidine	7	5	true	positive	Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.  Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.  Quinidine    Small doses of quinidine completely inhibit the CYP2D6 hydroxylation metabolic pathway, making all patients, in effect, slow metabolizers [see Clinical Pharmacology (12)].	9068	2541
194	quinidine	fluoxetine	7	6	true	positive	Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.  Quinidine    Small doses of quinidine completely inhibit the CYP2D6 hydroxylation metabolic pathway, making all patients, in effect, slow metabolizers [see Clinical Pharmacology (12)].	9068	4493
194	quinidine	propafenone	7	5	true	positive	Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.  Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.  Quinidine    Small doses of quinidine completely inhibit the CYP2D6 hydroxylation metabolic pathway, making all patients, in effect, slow metabolizers [see Clinical Pharmacology (12)].	9068	8754
194	warfarin	digoxin	19	17	true	positive	7.2 Digoxin    Concomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%.  Monitor plasma digoxin levels of patients receiving propafenone and adjust digoxin dosage as needed.  7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.	11289	3407
194	warfarin	orlistat	19	21	true	positive	7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.  Adjust the warfarin dose as needed by monitoring INR (international normalized ratio).  7.4 Orlistat    Orlistat may limit the fraction of propafenone available for absorption.	11289	37925
194	warfarin	propafenone	19	17	true	positive	7.2 Digoxin    Concomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%.  Monitor plasma digoxin levels of patients receiving propafenone and adjust digoxin dosage as needed.  7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.	11289	8754
194	warfarin	warfarin	19	19	true	positive	7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.	11289	11289
195	isoproterenol	propafenone	7	5	true	positive	Propafenone reduces spontaneous automaticity and depresses triggered activity.  Studies in anesthetized dogs and isolated organ preparations show that propafenone has beta-sympatholytic activity at about 1/50 the potency of propranolol.  Clinical studies employing isoproterenol challenge and exercise testing after single doses of propafenone indicate a beta-adrenergic blocking potency (per mg) about 1/40 that of propranolol in man.	6054	8754
195	propafenone	procaine	9	11	true	positive	At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium, but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy.  Moreover, propafenone inhibits a variety of cardiac potassium currents in in vitro studies (i.e. the transient outward, the delayed rectifier, and the inward rectifier current).  Propafenone has local anesthetic activity approximately equal to procaine.	8754	8701
195	propafenone	propranolol	5	6	true	positive	Propafenone reduces spontaneous automaticity and depresses triggered activity.  Studies in anesthetized dogs and isolated organ preparations show that propafenone has beta-sympatholytic activity at about 1/50 the potency of propranolol.	8754	8787
197	phenytoin	phenytoin	46	46	true	negative	However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed.	8183	8183
197	phenytoin	zidovudine	46	46	true	negative	However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed.	8183	11413
197	ribavirin	lamivudine	49	49	true	negative	However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].	9344	68244
197	ribavirin	phenytoin	49	47	true	negative	Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin.  Ribavirin:  In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine.  However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].	9344	8183
197	ribavirin	ribavirin	49	49	true	negative	However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].	9344	9344
197	ribavirin	zidovudine	49	47	true	negative	Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin.  Ribavirin:  In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine.  However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].	9344	11413
197	stavudine	lamivudine	49	49	true	negative	However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].	59763	68244
197	stavudine	ribavirin	49	49	true	negative	However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].	59763	9344
197	stavudine	zidovudine	49	47	true	negative	Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin.  Ribavirin:  In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine.  However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].	59763	11413
197	zidovudine	thymidine	8	10	true	positive	GZDV AUC is about 3-fold greater than the zidovudine AUC.  Urinary recovery of zidovudine and GZDV accounts for 14% and 74%, respectively, of the dose following oral administration.  A second metabolite, 3'-amino-3'-deoxythymidine (AMT), has been identified in the plasma following single-dose intravenous (IV) administration of zidovudine.	11413	1372538
199	zidovudine	methadone	1	1	true	positive	Zidovudine    Experimental evidence demonstrated that methadone increased the area under the concentration-time curve (AUC) of zidovudine which could result in toxic effects.	11413	6813
199	zidovudine	zidovudine	1	1	true	positive	Zidovudine    Experimental evidence demonstrated that methadone increased the area under the concentration-time curve (AUC) of zidovudine which could result in toxic effects.	11413	11413
